Drug intelligence / Profile preview

phosphatidylcholine (LT-02)

Development stage: Discontinued
Lead developer: Lipid Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

LT-02 is a novel, highly purified, oral controlled-release formulation of phosphatidylcholine specifically designed to treat ulcerative colitis by improving the barrier function of the mucosal layer of the colon. It is intended for patients with mild to moderate ulcerative colitis who have an inadequate response to mesalamine. The drug aims to augment the natural protective mucosal barrier in the lower gut and targets pathological changes in gut barrier function thought to underlie ulcerative colitis[4][5][6].

Other names: modified-release phosphatidylcholinedelayed release phosphatidylcholinegastro-resistant phosphatidylcholine granules

Targets

Intestinal mucosal phospholipid layer

Beyond the preview

Go deeper on phosphatidylcholine (LT-02).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phosphatidylcholine (LT-02).

Explore the full profile